Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
RC

NYSE · RCUS

Arcus Biosciences, Inc.

Healthcare · Biotechnology

$18.19

Down-$0.42 (-2.26%)

Updated Nov 1, 2026, 5:24 AM

SID Score

4.1/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.72B
P/E ratio
-7.68
Dividend yield
0.00%
52-week range
$17.43 – $31.74
Volume
1.94M
Avg. volume
1.53M

Price performance · RCUS

RCUS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

RCUS closed at $18.19 after 20 trading sessions, down 26.48% for the selected period.

Last close
$18.19
Period change
-26.48%
Period low
$17.76
Period high
$24.74
Daily close
View OHLC price history
RCUS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$18.34$18.895$17.81$18.191.94M
Oct 29, 2026$18.62$19.0235$18.115$18.611.67M
Oct 28, 2026$17.85$18.505$17.76$18.392.02M
Oct 27, 2026$17.62$18.33$17.53$18.142.23M
Oct 26, 2026$18.37$18.615$17.63$17.762.7M
Oct 23, 2026$19.02$19.09$18.43$18.545.93M
Oct 22, 2026$17.43$19.62$17.43$19.368.37M
Oct 21, 2026$24.47$24.47$18.98$19.104.65M
Oct 20, 2026$21.26$24.70$20.81$23.756.24M
Oct 19, 2026$22.44$22.94$21.37$22.143.52M
Oct 16, 2026$22.79$22.955$21.60$22.121.43M
Oct 15, 2026$22.53$23.28$22.53$22.821.21M
Oct 14, 2026$22.82$23.47$22.36$22.531.21M
Oct 13, 2026$23.87$24.005$22.46$22.511.39M
Oct 12, 2026$24.42$24.73$24.12$24.341.34M
Oct 9, 2026$23.89$24.58$23.75$24.41795.19K
Oct 8, 2026$24.29$24.38$22.80$23.831.86M
Oct 7, 2026$24.225$24.85$23.90$24.521.6M
Oct 6, 2026$24.96$24.96$23.96$24.28824.85K
Oct 5, 2026$24.19$24.95$24.105$24.741.39M

Latest RCUS news

The latest Smart Investors Daily articles mentioning RCUS.

Stock researchCompany · Overview

RCUS research

Overview

Company profile and research snapshot.

Company profile

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.50
Implied upside
—
Analysts
—
RCUS recent ratings
DateFirmRatingTarget
Oct 21, 2026WedbushOutperform—
Oct 21, 2026Truist SecuritiesBuy—
Oct 21, 2026CitigroupBuy—
Oct 16, 2026William BlairOutperform—
Oct 14, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., October 26, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 10,650 shares of the Company’s common stock at an exercise price per share of $18.54, which was the closing pric

Yahoo · Oct 24, 2026

How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share Sale

Arcus Biosciences completed a US$250.0 million follow-on equity offering of 14,285,715 common shares at US$17.50 each, following recent casdatifan data updates in clear cell renal cell carcinoma. The equity raise signals management prioritising funding for late-stage development of casdatifan across multiple RCC treatment lines, along with broader registrational trial plans. The next area of focus is how this Arcus Biosciences capital raise could reshape the investment narrative around...

Yahoo · Oct 24, 2026

Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses

Arcus Biosciences has pulled back sharply in recent weeks, even though investors are still digesting fresh trial data and a sizeable equity raise. For anyone looking at the stock today, the key question is whether the current share price is reasonable when compared with the revenue Arcus is generating. Over the past 5 years the share price has fallen 44.6%, which puts the spotlight firmly on whether the business now justifies its market value through its sales profile. New kidney cancer data...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By